CDK1 and neoplasm: Moreover, AS/BJO-NEs can inhibit this series of processes by suppressing the expression of CDK1 and regulating MTFR2, thereby inhibiting the onset and progression of neoplasms, and modulating the tumor microenvironment and inflammatory environment.